Zynerba Pharmaceuticals, Inc. (ZYNE)
Upgrades & Downgrades
Latest ZYNE news
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
9 January 2023
Want to try a different approach? Tap five stocks with increasing P/E ratios.
Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial...
21 December 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolesc...
Zynerba Pharmaceuticals announces positive long-term data from Phase 2 INSPIRE trial at annual meeti...
5 December 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Arizon...
Zynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X p...
28 November 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced that Fragile X patients treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with a placebo in a recen...
Zynerba Pharmaceuticals granted orphan drug designation by EC for Zygel active ingredient to treat 2...
15 November 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reported it has further advanced its transdermal gel Zygel—receiving orphan drug designation from the European Commission (EC) for the gel's active ingredient...
Zynerba ends 3Q with robust $55.9M cash runway to advance its Zygel CBD Gel for Fragile X Syndrome
14 November 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), which works on innovative pharmaceutically produced transdermal cannabinoid therapies for neuropsychiatric disorders, posted results for the third quarter th...
Zynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product candidate, Zy...
2 November 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has announced that the US Patent and Trademark Office has issued Patent No. 11,458,109, titled "Treatment of 22q11.2 Deletion Syndrome With Cannabidiol," whic...
Zynerba Pharma presents positive data from Phase 2 INSPIRE trial at NORD Rare Diseases and Orphan Pr...
17 October 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held Oc...
Zynerba Pharmaceuticals receives new US patent for its cannabidiol formulated gel Zygel
6 October 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has boosted its international intellectual property (IP) portfolio, revealing it has been granted a new US patent for its cannabidiol-formulated gel Zygel. Th...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
22 September 2022
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi...